NV-HISENSE
5.1.2023 18:01:49 CET | Business Wire | Press release
The Hisense Group is pleased to announce that it has joined the Connectivity Standards Alliance and will bring support for the Matter protocol to its products starting in 2023, helping to simplify and elevate consumers’ experience through seamless integration and interoperability of all their smart home devices. Hisense Group's portfolio includes consumer electronics and home appliance brands such as Hisense, Toshiba, Gorenje, ASKO, and ATAG, as well as smart device platforms such as ConnectLife and VIDAA.
These brands will grow to include Matter compatible electronics and appliances going forward.
Matter is a new, open smart home protocol supported by many companies, both major leaders and smaller players, creating an unmatched force in the future of smart homes. Matter strives to ensure seamless connectivity of all devices, from a lightbulb to smart TVs to major domestic appliances, without worrying about compatibility.
“As the world’s #2 and China's #1 TV manufacturer and a top tier manufacturer for home appliances, Hisense is committed to enhancing consumers’ lives and experiences with the adoption of Matter,” said David Gold, President of Hisense USA. “Matter will enable consumers to enjoy all the core features and benefits that the Hisense Group’s products offer while integrating seamlessly with their preferred apps and smart devices to help streamline and maximize their smart home setup.”
“The adoption of Matter by our member Hisense is another example of a global consumer electronics company seeing the value that it brings to the IoT ecosystem, delivering a more secure, open standard that benefits consumers and manufacturers alike,” said Chris LaPre, Head of Technology, Connectivity Standards Alliance. “We’re excited to see how quickly the standard is becoming a must-have component to categories like televisions and appliances, and we value the global scale that Hisense brings to the table.”
Thanks to Matter, users will be able to use all their Matter enabled smart devices on the same platform. Once set up, it will be easy to connect all Matter devices with preferred apps and ecosystems and enable the use of basic applications - such as the simple operation of devices and integration into smart home systems. With that, upcoming generations of smart devices from the Hisense Group will be Matter compatible.
About Hisense
Hisense is headquartered in Qingdao, China. In the past 54 years, Hisense has always been adhering to the core values of "Integrity, Innovation, Customer Focus, and Sustainability" and the development strategy of "Sound Technological Foundation and Robust Operation". The business covers areas including multimedia, home appliances, IT intelligent information and modern service industries. With the rapid development in recent year, Hisense business is expended to more than 160 countries and regions. Smart TV which is the core of Hisense B2C business has always been at the forefront of the global industry. Besides B2C, Hisense is also in the global leading place in B2B industries including Intelligent Transportation, Precision Medicine and Optical Communications.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230105005382/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom